Nektar Therapeutics/$NKTR
1D1W1MYTD1Y5YMAX
Capital at risk
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
- Ticker
- $NKTR
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 63
- Headquarters
- San Francisco, United States
- Website
- www.nektar.com
NKTR Metrics
BasicAdvanced
$2.3B
-
-$6.47
1.16
-
Price and volume
Market cap
$2.3B
Beta
1.16
52-week high
$109.00
52-week low
$33.40
Average daily volume
643K
Financial strength
Current ratio
10.416
Quick ratio
9.641
Long term debt to equity
0.125
Total debt to equity
0.151
Interest coverage (TTM)
-4.22%
Profitability
EBITDA (TTM)
-129.95
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-287.84%
Operating margin (TTM)
-239.32%
Effective tax rate (TTM)
-0.04%
Revenue per employee (TTM)
$870,000
Management effectiveness
Return on assets (TTM)
-12.54%
Return on equity (TTM)
-35.75%
Valuation
Price to revenue (TTM)
29.985
Price to book
2.47
Price to tangible book (TTM)
2.55
Price to free cash flow (TTM)
-6.973
Free cash flow yield (TTM)
-14.34%
Free cash flow per share (TTM)
-9.662
Growth
Revenue change (TTM)
-27.15%
Earnings per share change (TTM)
-25.83%
3-year revenue growth (CAGR)
-14.63%
10-year revenue growth (CAGR)
-11.77%
3-year earnings per share growth (CAGR)
-35.80%
10-year earnings per share growth (CAGR)
-7.77%
Upcoming events
No upcoming events
NKTR News
AllArticlesVideos
Funds containing NKTR
AllEURGBPUSD
Fund name | Fund size | $NKTR weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.08% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.03% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.03% |
Xtrackers S&P 500 Swap£XSPX | £3.1B | 0.02% |
iShares MSCI World Small Cap$WSML | $9B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.